Moderna and Merck report successful Phase 3 trial results for personalized mRNA melanoma vaccine
Here's what it means for you.
This breakthrough in cancer treatment could reshape therapeutic options for high-risk patients globally.
What happened
On August 19, 2026, Moderna and Merck announced positive Phase 3 trial results for their personalized mRNA vaccine in high-risk melanoma patients.
The Context
- Innovative Approach: The trial utilized mRNA technology, previously successful in COVID-19 vaccines, to create tailored cancer therapies based on individual tumor mutations.
- Significant Study Size: The INTerpath-001 trial involved 1,137 patients, providing robust data on the vaccine's efficacy in preventing cancer recurrence.
- Market Impact: Following the announcement, Moderna's stock surged, reflecting investor confidence in the potential of mRNA cancer vaccines.
The Number
— This is the number of patients enrolled in the Phase 3 INTerpath-001 trial, highlighting the scale and significance of the study in evaluating new cancer treatments.
Takeaway
As detailed data is set to be presented at an upcoming medical meeting, the results may pave the way for broader applications of mRNA technology in oncology.
International news coverage curated for readers in the UAE and Gulf region.
"Emirates 24|7 world coverage presents global developments through a UAE-facing and Gulf-relevant editorial lens."
— A47 Editor
Moderna, Merck breakthrough could usher in wave of cancer vaccines
Merck and Moderna have announced a breakthrough in cancer treatment with a personalized mRNA vaccine designed to prevent the recurrence of melanoma, showing promising results in a large clinical trial involving over 1,000 patients. This innovative ap...
Scientific research, technology, environment, and society.
"Scientific American is one of the oldest and most authoritative science magazines, known for deep dives into science, technology, and society."
— A47 Editor
Moderna and Merck announce ‘landmark’ trial showing mRNA therapy significantly cuts odds of recurrent skin cancer
Moderna and Merck have announced a significant breakthrough in cancer treatment with their mRNA therapy, which has shown to substantially reduce the chances of recurrent melanoma in a landmark trial. This innovative approach harnesses the body's immu...
Science and technology stories including AI.
"Longstanding science magazine with thoughtful AI coverage."
— A47 Editor
Moderna and Merck announce ‘landmark’ trial showing mRNA therapy significantly cuts odds of recurrent skin cancer
Moderna and Merck have announced a significant breakthrough in cancer treatment with their mRNA therapy, which has shown to substantially reduce the chances of recurrent melanoma in a landmark trial. This innovative approach harnesses the body's immu...
Global news coverage with extensive reporting on Middle Eastern conflicts and geopolitics.
"Al Jazeera is a Qatar-based broadcaster known for wide regional coverage and alternative perspectives."
— A47 Editor
Moderna, Merck unveil mRNA-based cancer vaccine that cuts spread
Moderna and Merck have announced the successful results of their late-stage trials for Intismeran, an mRNA-based vaccine designed to reduce the recurrence and spread of melanoma, a serious form of skin cancer. This innovative approach leverages mRNA ...
Comprehensive coverage of Middle Eastern and global issues.
"Al Jazeera is a prominent voice from the Global South, especially the Middle East, with an emphasis on underreported stories."
— A47 Editor
Moderna, Merck unveil mRNA-based cancer vaccine that cuts spread
Moderna and Merck have announced the successful results of their late-stage trials for Intismeran, an mRNA-based vaccine designed to reduce the recurrence and spread of melanoma, a serious form of skin cancer. This innovative approach leverages mRNA ...
Conservative-leaning political and national coverage.
"The Washington Times is a conservative-leaning newspaper known for its political coverage and advocacy of right-of-center viewpoints."
— A47 Editor
Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test
Moderna's shares surged over 100% following the announcement of promising initial results from a study of its experimental mRNA cancer treatment, which, if approved, would be the first of its kind. This significant milestone reflects the company's on...
Canadian and international health news, medicine, public policy, and research.
"Global News is a mainstream Canadian outlet generally considered to have a centrist editorial stance, covering news with a focus on factual reporting and national interest."
— A47 Editor
Moderna’s experimental mRNA cancer treatment progresses, shares spike
Moderna and Merck are advancing their experimental mRNA cancer treatment, which is designed to be personalized based on the unique mutations found in individual tumors. This innovative approach aims to enhance the effectiveness of cancer vaccines by ...
Corporate leadership, finance, technology, and market trends.
"Fortune covers financial trends, leadership, and innovation with a pragmatic editorial approach."
— A47 Editor
Moderna’s and Merck’s personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring
Moderna and Merck's personalized mRNA vaccine has shown significant promise in a late-stage trial, reducing the risk of melanoma recurrence among over 1,100 patients when combined with Merck's Keytruda. This breakthrough has led to a surge in stock p...
Medical headlines, wellness tips, and public health guidance.
"ABC News delivers broad national coverage with a mainstream editorial stance, focusing on accessibility and balanced reporting."
— A47 Editor
Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test
Moderna's shares surged over 100% following the announcement of promising initial results from a study of its experimental mRNA cancer treatment, indicating a significant advancement in the company's oncology research efforts.
In-depth coverage of hardware, software, science, and policy.
"Ars Technica provides expert technology news, hardware reviews, and analysis for a technically savvy audience."
— A47 Editor
mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
Moderna and Merck announced that their mRNA cancer vaccine has successfully completed a Phase 3 trial for melanoma, demonstrating its ability to prevent the return and spread of the disease. This achievement marks a significant milestone in the devel...
In-depth reporting on tech, policy, and science including AI.
"Respected analysis for technically savvy readers, including AI topics."
— A47 Editor
mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
Moderna and Merck announced that their mRNA cancer vaccine has successfully completed a Phase 3 trial for melanoma, demonstrating its ability to prevent the return and spread of the disease. This achievement marks a significant milestone in the devel...
Health trends, medical research, and fitness reporting.
"The New York Times is a globally recognized newspaper offering authoritative reporting with a center-left editorial stance."
— A47 Editor
Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
Moderna and Merck announced that their experimental mRNA vaccine has successfully prevented the recurrence and spread of melanoma in high-risk patients, marking a significant advancement in cancer treatment. This development was reported during ongoi...
Scientific research, space, environment, and health coverage.
"The New York Times is a globally recognized newspaper offering authoritative reporting with a center-left editorial stance."
— A47 Editor
Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
Moderna and Merck announced that their experimental mRNA vaccine has successfully prevented the recurrence and spread of melanoma in high-risk patients, marking a significant advancement in cancer treatment. This development was reported during ongoi...
Global business headlines with AI angles.
"General business outlet that frequently covers AI."
— A47 Editor
Possible Skin Cancer Vaccine Shows Promise In Late Stage Trial. Moderna Stock Skyrockets.
A late-stage clinical trial for a potential skin cancer vaccine developed by Moderna has shown promising results, marking a significant milestone in cancer treatment research. This development has been described as a 'landmark moment' for the company...
Capitol Hill news, legislation, and policy insight.
"The Hill specializes in U.S. politics and policy, with a focus on Capitol Hill developments and a reputation for insider reporting."
— A47 Editor
Moderna, Merck mRNA cancer vaccine prevents melanoma from returning
An experimental personalized mRNA-based cancer vaccine developed by Merck and Moderna has shown success in preventing the recurrence or spread of melanoma in a late-stage trial involving high-risk patients. The companies announced these positive resu...
Arabic-language sports reporting covering UAE competitions and major international events.
"Emarat Al Youm sports coverage is mainstream and accessible, with strong emphasis on UAE and regional sport."
— A47 Editor
نتائج أولية إيجابية للقاح تجريبي مخصص لسرطان الجلد الميلانيني نتائج أولية إيجابية للقاح تجريبي مخصص لسرطان الجلد الميلانيني
A preliminary positive result has been reported for an experimental vaccine targeting melanoma, developed by Moderna and Merck, marking a significant milestone in its first trial phase.
Tech startup news, programming trends, and discussions shared by the developer community.
"Hacker News is a community-driven source highlighting influential tech discussions, startup launches, and programming insights."
— A47 Editor
Moderna reports first positive Phase 3 for mRNA neoantigen therapy in melanoma
Moderna has reported its first positive results from a Phase 3 trial of its mRNA neoantigen therapy for melanoma, marking a significant advancement in the company's efforts to develop personalized cancer treatments. This therapy aims to harness the b...
Health, medicine, wellness, and public health coverage with a UAE angle.
"Emirates 24|7 health coverage leans toward accessible reporting on healthcare updates, medical milestones, and wellness topics."
— A47 Editor
Moderna shares soar after cancer vaccine cuts melanoma recurrence
Moderna's personalized mRNA cancer vaccine, developed in collaboration with Merck, has shown promising results in a late-stage clinical trial, significantly reducing the risk of melanoma recurrence and cancer spread when combined with Merck's Keytrud...
Business, investment, entrepreneurship, leadership, and innovation.
"Forbes is known for its coverage of business leaders, market trends, and entrepreneurial ventures with a pro-business editorial stance."
— A47 Editor
Moderna Shares Skyrocket 90% Toward Best Day Ever—On Success Of Cancer Drug Trial
Moderna's shares surged by 90% following the announcement of a successful final-stage trial for its mRNA-based cancer therapy, marking a significant milestone in cancer treatment. This trial is the first of its kind to demonstrate success, highlighti...
Tech industry news, innovation, gadgets, and startups from a UK broadcaster.
"Sky News is often seen as a center-right outlet in the UK, known for its rolling coverage and breaking stories."
— A47 Editor
Moderna's share price nearly doubles on hopes of cancer treatment breakthrough
Moderna's share price has surged nearly 100% following optimism surrounding a potential breakthrough in personalized cancer treatment, marking a significant milestone for the company.
UK and global business, economy, and markets coverage.
"Sky News is often seen as a center-right outlet in the UK, known for rolling news and breaking business stories."
— A47 Editor
Moderna's share price nearly doubles on hopes of cancer treatment breakthrough
Moderna's share price has surged nearly 100% following optimism surrounding a potential breakthrough in personalized cancer treatment, marking a significant milestone for the company.